Marina Cavazzana1, Fabien Touzot, Despina Moshous, Bénédicte Neven, Stéphane Blanche, Alain Fischer. 1. aBiotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris bBiotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM cParis Descartes - Sorbonne Paris Cité University, Imagine Institute dINSERM UMR 1163, Laboratory of Human Lymphohematopoiesis eImmunology and Pediatric Hematology Department, Assistance Publique-Hôpitaux de Paris fCollège de France, Paris, France.
Abstract
PURPOSE OF REVIEW: Primary immunodeficiencies (PIDs) constitute a heterogeneous group of inherited disorders affecting the development and/or function of the immune system. This review focuses on the recent advances in hematopoietic stem cell transplantation (HSCT) for PIDs, as it remains the only potentially curative option for many of these diseases. RECENT FINDINGS: We report on the most recent HSCT European results and suggest some opportunities for better treatment of certain PIDs. Progress on gene therapy is also discussed, as it emerges as an interesting option for PIDs management. SUMMARY: Progress in the treatment of primary immune deficiency with HSCT requires a better understanding of the pathophysiology and specificity of each of these diseases, allowing us to determine the best options in terms of donor, conditioning regimen, modification of the allograft and immunosuppressive therapy. Alternative therapies - such as gene therapy - emerge as an interesting option for some PIDs.
PURPOSE OF REVIEW: Primary immunodeficiencies (PIDs) constitute a heterogeneous group of inherited disorders affecting the development and/or function of the immune system. This review focuses on the recent advances in hematopoietic stem cell transplantation (HSCT) for PIDs, as it remains the only potentially curative option for many of these diseases. RECENT FINDINGS: We report on the most recent HSCT European results and suggest some opportunities for better treatment of certain PIDs. Progress on gene therapy is also discussed, as it emerges as an interesting option for PIDs management. SUMMARY: Progress in the treatment of primary immune deficiency with HSCT requires a better understanding of the pathophysiology and specificity of each of these diseases, allowing us to determine the best options in terms of donor, conditioning regimen, modification of the allograft and immunosuppressive therapy. Alternative therapies - such as gene therapy - emerge as an interesting option for some PIDs.
Authors: Afshin A Khan; Bassam N Estfan; Anirudh Yalamanchali; Djibril Niang; Erica C Savage; Clifton G Fulmer; Hailey L Gosnell; Jamak Modaresi Esfeh Journal: World J Clin Oncol Date: 2022-06-24
Authors: Thomas Magg; Tilmann Schober; Christoph Walz; Julia Ley-Zaporozhan; Fabio Facchetti; Christoph Klein; Fabian Hauck Journal: Front Immunol Date: 2018-02-27 Impact factor: 7.561
Authors: Per Holmfeldt; Miguel Ganuza; Himangi Marathe; Bing He; Trent Hall; Guolian Kang; Joseph Moen; Jennifer Pardieck; Angelica C Saulsberry; Alba Cico; Ludovic Gaut; Daniel McGoldrick; David Finkelstein; Kai Tan; Shannon McKinney-Freeman Journal: J Exp Med Date: 2016-02-15 Impact factor: 14.307